GSK Strategic Moves in U.K. to Result in New Investments, Possible Plant Closure, Some Job Losses

(Editor's Note: Exchange rates calculated at £1 = $1.30 on July 20, 2017) In pharmaceuticals, the company is to undertake a strategic review of its cephalosporins antibiotics business, with an option to sell the business including the associated manufacturing facilities. Philip Thomson, preside...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical Processing
Main Author plc, GlaxoSmithKline
Format Trade Publication Article
LanguageEnglish
Published Rockaway Advantage Business Media 20.07.2017
Subjects
Acquisitions & mergers
Antibiotics
Manufacturing
Pharmaceutical industry
United Kingdom > UK
Italy
Scotland
Online AccessGet full text

Cover

More Information
Summary:(Editor's Note: Exchange rates calculated at £1 = $1.30 on July 20, 2017) In pharmaceuticals, the company is to undertake a strategic review of its cephalosporins antibiotics business, with an option to sell the business including the associated manufacturing facilities. Philip Thomson, president, Global Affairs, GSK, said: “We are continuing to invest in science and our core businesses in the U.K. and we continue to see the U.K. as an attractive place for the life...
ISSN:1049-9156